Could an immune-boosting pill make melanoma treatments work better?
NCT ID NCT02073123
First seen Jun 01, 2026 · Last updated Jun 20, 2026 · Updated 2 times
Summary
This study tested a drug called indoximod, taken as a pill, together with standard immune checkpoint inhibitors (ipilimumab or pembrolizumab) in 131 adults with advanced or metastatic melanoma that could not be removed by surgery. The goal was to see if the combination was safe and improved tumor shrinkage. The trial has been completed, and results may help design future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Augusta University
Augusta, Georgia, 30912, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
New Mexico Cancer Center Alliance
Albuquerque, New Mexico, 87106, United States
-
Penn State Hershey Cancer Institue
Hershey, Pennsylvania, 17033, United States
-
University of Iowa Hospital and Clinics
Iowa City, Iowa, 52242, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Indoximod (a drug that may boost the immune system against cancer)
What this could lead to
If successful, this combination could improve response rates and survival for people with advanced melanoma that cannot be surgically removed.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. The combination may cause significant side effects or fail to improve outcomes over existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.